R. Loomba

Epidemiology · 2013–2024

A researcher in the Science corpus: 18 papers; trusts 6 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Epidemiology — 262 citations into it; #747 of 2,148 by trust here, #156 by citations
• Hepatology — 155 citations into it; #35 of 151 by trust here, #20 by citations
• Endocrinology, Diabetes and Metabolism — 140 citations into it; #227 of 623 by trust here, #102 by citations
• Pathology and Forensic Medicine — 50 citations into it
• Oncology — 33 citations into it
• Biochemistry — 7 citations into it

Whom R. Loomba trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Z. Younossi
2. L. Adams
3. V. Samuel
4. Andy Liaw
5. A. Villanueva
6. J. Y. Chiang
7. K. Petersen
8. A. Sanyal
9. J. Browning
10. D. Kleiner

Who trusts R. Loomba overall

1. Mashun Onishi
2. S. Friedman
3. Megan H. Bair-Merritt
4. Z. Younossi
5. Koji Yamano
6. C. Estes
7. Amit G. Singal

Papers from R. Loomba's perspective

Ordered by how strongly the researchers R. Loomba trusts endorse each paper. Same corpus, a different order for every researcher.

1. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the… (American Journal of Gastroenterology)
2. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. (Gastroenterology)
3. Design and validation of a histological scoring system for nonalcoholic fatty liver disease (Hepatology)
4. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. (Gastroenterology)
5. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. (Clinical Gastroenterology and Hepatology)
6. Nonalcoholic fatty liver disease: a systematic review. (Journal of the American Medical Association (JAMA))
7. Molecular mediators of hepatic steatosis and liver injury. (Journal of Clinical Investigation)
8. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease (Nature Genetics)
9. Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* (Journal of Biological Chemistry)
10. Nonalcoholic fatty liver disease. (Revista de Gastroenterología de México)

Their papers

• A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. (2024) — 1,246 citations
• AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (2023) — 1,742 citations
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
• Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease (2021) — 821 citations
• Mechanisms and disease consequences of nonalcoholic fatty liver disease (2021) — 1,660 citations
• Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
• Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease (2019) — 1,285 citations
• Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) — 1,677 citations
• The gut-liver axis and the intersection with the microbiome (2018) — 1,264 citations
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017) — 2,091 citations
• Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease (2017) — 758 citations
• Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis (2017) — 1,682 citations
• Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events (2016) — 808 citations
• Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease (2016) — 648 citations
• Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. (2015) — 1,579 citations
• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014) — 2,063 citations
• The global NAFLD epidemic (2013) — 1,687 citations